Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)

You may be eligible if

• Received one or more injections of Rebif® for treatment of a demyelinating event
• Be younger than 18 years of age at time of Rebif® treatment initiation
• Rebif® therapy must have been initiated before June 30, 2009